Abstract PS3-08-27: Repower: a real-world noninterventional study of outcomes and experiences in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) early breast cancer (EBC) treated with an adjuvant cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) plus endocrine therapy (ET)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Yale University, Sun Yat-sen University, Hospital Universitario Virgen del Rocío, University of Reading, Institut de Cancérologie de l'Ouest, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Hospital Universitario Ramón y Cajal, Novartis (France), Novartis (Switzerland), Novartis (United States), Novartis (Ireland), Royal Marsden NHS Foundation Trust, Royal Marsden Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129472138
Cites:
Cited by:
Related to: